Odonate Therapeutics, Inc. is a pharmaceutical company dedicated to the development of best-in-class therapeutics that improve and extend the lives of patients with cancer. Odonate’s initial focus is on the development of tesetaxel, an investigational, orally administered chemotherapy agent that belongs to a class of drugs known as taxanes, which are widely used in the treatment of cancer. Odonate’s goal for tesetaxel is to develop an effective chemotherapy choice for patients that provides quality-of-life advantages over current alternatives.
Company profile
Ticker
ODTC, ODTCD
Exchange
Website
CEO
Kevin C. Tang
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Odonate Therapeutics, LLC
SEC CIK
ODTC stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
7 Feb 22
EFFECT
Notice of effectiveness
31 Jan 22
EFFECT
Notice of effectiveness
31 Jan 22
EFFECT
Notice of effectiveness
31 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 22
POS AM
Prospectus update (post-effective amendment)
26 Jan 22
S-8 POS
Registration of securities for employees (post-effective amendment)
26 Jan 22
POS AM
Prospectus update (post-effective amendment)
26 Jan 22
POS AM
Prospectus update (post-effective amendment)
26 Jan 22
25-NSE
Exchange delisting
25 Jan 22
Latest ownership filings
SC 13G/A
Ikarian Capital, LLC
14 Feb 22
SC 13G/A
JANUS HENDERSON GROUP PLC
10 Feb 22
SC 13G/A
BML Investment Partners, L.P.
28 Jan 22
SC 13G
BML Investment Partners, L.P.
28 Jan 22
4
Change in insider ownership
10 Dec 21
SC 13G/A
EcoR1 Capital, LLC
10 Dec 21
SC 13D/A
Boxer Capital, LLC
26 Nov 21
4
JOSEPH LEWIS
24 Nov 21
SC 13D/A
Boxer Capital, LLC
22 Nov 21
4
Aaron I. Davis
19 Nov 21
Financial summary
Quarter (USD) | Sep 21 | Jun 21 | Mar 21 | Dec 20 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 20 | Dec 19 | Dec 18 | Dec 17 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 95.74 mm | 95.74 mm | 95.74 mm | 95.74 mm | 95.74 mm | 95.74 mm |
Cash burn (monthly) | 5.03 mm | 7.77 mm | 4.67 mm | 8.53 mm | 5.03 mm | 7.88 mm |
Cash used (since last report) | 154.40 mm | 238.34 mm | 143.33 mm | 261.58 mm | 154.40 mm | 241.68 mm |
Cash remaining | -58.66 mm | -142.60 mm | -47.59 mm | -165.84 mm | -58.66 mm | -145.94 mm |
Runway (months of cash) | -11.7 | -18.4 | -10.2 | -19.4 | -11.7 | -18.5 |
Institutional ownership, Q1 2023
13F holders | Current |
---|---|
Total holders | 2 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 33.10 mm |
Total shares | 15.81 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
Tang Capital Partners | 12.96 mm | $30.19 mm |
BML Investment Partners | 2.85 mm | $2.91 mm |